212 related articles for article (PubMed ID: 32435969)
1. Antifungal prophylaxis during 7 + 3 induction chemotherapy for acute myeloid leukemia is associated with improved survival, in a setting with low incidence of invasive mold infections.
Hsu A; Matera R; Vieira K; Reagan JL; Farmakiotis D
Support Care Cancer; 2021 Feb; 29(2):707-712. PubMed ID: 32435969
[TBL] [Abstract][Full Text] [Related]
2. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
3. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
[TBL] [Abstract][Full Text] [Related]
4. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
[TBL] [Abstract][Full Text] [Related]
6. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
7. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
8. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
[TBL] [Abstract][Full Text] [Related]
10. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.
Martino R; Garrido A; Santaliestra M; García-Cadenas I; Novelli S; Saavedra SD; Esquirol A; Granell M; Briones J; Moreno C; Brunet S; Giménez A; Hidalgo A; Sánchez F; Sierra J
Mycopathologia; 2020 Aug; 185(4):639-652. PubMed ID: 32564177
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis.
Signorelli J; Lei M; Lam J; Jalbut M; Amrein PC; Fathi AT; Hobbs G; Hock H; McAfee SL; Letourneau AR; Narayan R; Brunner A
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e883-e889. PubMed ID: 32917574
[TBL] [Abstract][Full Text] [Related]
12. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
[TBL] [Abstract][Full Text] [Related]
13. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
16. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.
Ozga M; Huang Y; Blachly JS; Grieselhuber NR; Wall S; Larkin K; Haque T; Walker AR; Bhatnagar B; Behbehani G; Vasu S; Maakaron JE; Lustberg M; Mims AS
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e76-e83. PubMed ID: 32921593
[TBL] [Abstract][Full Text] [Related]
17. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia].
Gong BF; Liu YT; Zhang GJ; Wei SN; Li Y; Liu KQ; Gong XY; Zhao XL; Qiu SW; Gu RX; Lin D; Wei H; Zhou CL; Liu BC; Wang Y; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):528-531. PubMed ID: 28655098
[No Abstract] [Full Text] [Related]
18. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
19. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
